Justyna Śniadach

Mrs. Justyna Śniadach


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2021 in Life
Verified
Journal Article
Open access
PDF file
JŚJustyna Śniadach
Justyna Śniadach
SSSylwia Szymkowiak
Sylwia Szymkowiak
POPrzemysław Osip
Przemysław Osip
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
Depression and anxiety disorders are a serious and increasingly commonly diagnosed problem at present. The problem applies not only to adults but also, increasingly often, to children and adolescents as well. The outbreak of the COVID-19 pandemic has further compounded the issue. There are still relatively few publications that show that quarantine and social isolation have a negative effect on the psychological well-being of children and adolescents. Above all, the situation applies to children and adolescents with pre-existing predispositions and to individuals suffering from mental disorders. The key factor in this situation seems to be putting the needs of young people first so that they can safely return to school. It is also important to provide them with effective treatment strategies and methods with which to deal with this stressful and potentially traumatic situation. Most of the mental health research during the COVID-19 pandemic has been conducted in Asia and Europe, where the disease first spread. This article presents an overview of the results of the latest Polish and international studies on the increase in depression and anxiety disorders among children and adolescents during the COVID-19 pandemic worldwide. It concludes with recommendations regarding mental health support for young people, and further directions for treatment are suggested.

Verified
Journal Article
Open access
PDF file
JŚJustyna Śniadach
Justyna Śniadach
AKAleksandra Kicman
Aleksandra Kicman
SSSylwia Szymkowiak
Sylwia Szymkowiak
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
Exposure to microplastics (MPs) in biological systems can lead to particle toxicity, oxidative stress, and inflammatory changes, potentially contributing to cancer development, digestive disorders, respiratory issues, and fertility problems. Traditional cigarette users are particularly vulnerable, as MPs have been detected in 99% of cigarette filters, exposing smokers to these particles through inhalation and ingestion. This narrative review aims to analyze the sources, health implications, and biochemical impact of MPs derived from cigarette consumption. A literature search was conducted using databases such as PubMed, Scopus, and Google Scholar, applying strict inclusion criteria: peer-reviewed studies published between 2010 and 2025 and keywords such as “microplastics”, “smoking”, “tobacco”, “oxidative stress”, “pro-inflammatory cytokines”, “cell viability”, “regulatory policies”, and “health effects”. Findings indicate that MPs are present in biological samples such as blood (77% of cases), placenta (75%), lung tissue (88%), and feces (100%), demonstrating systemic human exposure. The environmental implications of improper cigarette disposal further exacerbate the global microplastic crisis. This review highlights potential mitigation strategies to reduce the health and environmental impact of cigarette-derived microplastics.

5 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JŚJustyna Śniadach
Justyna Śniadach
WOWiktor Orlof
Wiktor Orlof
JSJustyna Sołowiej-Chmiel
Justyna Sołowiej-Chmiel
AKAleksandra Kicman
Aleksandra Kicman
SSSylwia Szymkowiak
Sylwia Szymkowiak
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
Chemsex is a phenomenon involving the intentional use of psychoactive substances before or during sexual activity, especially among men who have sex with men (MSM). It is associated with various health risks, including substance dependence, risky sexual behaviors, and both mental and somatic disorders. Despite its growing prevalence and public health relevance, chemsex lacks a clear definition and is not recognized as a distinct diagnostic entity. This narrative review synthesizes clinical, epidemiological, and technological evidence on chemsex; argues for its classification as a form of mixed addiction; and preliminarily proposes diagnostic criteria for a potential entity in the International Classification of Diseases, 12th Revision (ICD-12). This paper highlights key psychotropic substances used in chemsex, patterns of use, and their neurobiological, psychological, and behavioral consequences. It explores the relationship between chemsex and compulsive sexual behavior disorder (CSBD), current diagnostic frameworks (ICD-10 and ICD-11), and challenges in clinical practice. Therapeutic strategies discussed include cognitive behavioral therapy (CBT), digital interventions, and emerging applications of artificial intelligence (AI) in prevention and treatment. Attention is also given to epidemiological trends, sociocultural influences, and barriers to seeking help. This review concludes by identifying research gaps and advocating for a more integrated, multidimensional approach to classifying and treating chemsex-related syndromes.

10 June 2026 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
JŚJustyna Śniadach
Justyna Śniadach
SSSylwia Szymkowiak
Sylwia Szymkowiak
POPrzemysław Osip
Przemysław Osip
WOWiktor Orlof
Wiktor Orlof
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
Background: Cannabis use has increased across Europe over the last decade, accompanied by growing availability of high-potency THC products and rising psychiatric presentations. Despite these trends, European countries differ substantially in monitoring systems, clinical preparedness and public health responses. These disparities are especially visible between Western Europe, which has more developed pharmacovigilance systems, diagnostic networks, and addiction psychiatry services, and other regions. Compared with other regions, in Central and Eastern Europe cannabis-related psychiatric complications remain systematically underestimated. Methods: We conducted a narrative review of peer-reviewed literature, epidemiological reports and national health data published between 2015 and 2025. Sources included EMCDDA, WHO Europe, national statistical agencies and clinical studies on psychiatric outcomes associated with cannabis use. Findings: Cannabis is the most commonly used illicit psychoactive substance in Europe, with higher prevalence in Western countries but rapid growth across Central and Eastern Europe. The proliferation of high-potency cannabis (>15–25%) is consistently linked to elevated risks of psychosis, anxiety, panic symptoms, derealisation episodes and cannabis use disorder. Western Europe demonstrates better detection of cannabis-related psychiatric presentations, whereas Central and Eastern Europe show a hidden clinical burden driven by stigma, limited screening, inconsistent diagnostic practices and the absence of structured monitoring systems. Health systems vary widely in preparedness, particularly regarding early identification of high-risk use, addiction psychiatry integration and routine collection of psychiatric outcome data. Interpretation: Cannabis use is linked to a growing mental health burden in Europe. Stronger THC products and uneven health systems make this problem worse. In Central and Eastern Europe, many cannabis-related mental health problems are missed or not reported. Better monitoring, clearer diagnostic rules, and coordinated action across Europe are needed.

13 July 2026 in Toxics
Verified
Journal Article
Open access
PDF file
JŚJustyna Śniadach
Justyna Śniadach
ASAleksandra Starosz
Aleksandra Starosz
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
KJKamila Jończyk
Kamila Jończyk
AMAnna Michalska-Falkowska
Anna Michalska-Falkowska
KGKamil Grubczak
Kamil Grubczak
Particles exhibiting fluorescence after Nile Red staining have been increasingly investigated in human biological samples in the context of microplastic exposure, but their clinical relevance remains unclear. In this study, Nile Red-positive microparticles were quantified in whole blood from chronic users of different nicotine-delivery systems and non-user controls. The study included 73 nicotine users, including conventional cigarette smokers, e-cigarette users, and heated tobacco product users, as well as an age- and sex-matched control group. Only participants without diagnosed chronic somatic disease were enrolled. Microparticles were quantified by flow cytometry after Nile Red staining. Associations with age, nicotine dependence assessed with the FTND and FTQ, motivation to quit smoking assessed with the Schneider Motivation Test, and selected hematological and biochemical parameters were also analyzed. In the overall analysis, the mean number of microparticles was higher in nicotine users than in controls, but the difference was not statistically significant (p = 0.38). In subgroup analyses, higher particle counts were observed in conventional cigarette smokers and heated tobacco product users compared with controls. No significant difference was found for e-cigarette users. Higher particle counts were also observed in older participants and in participants with greater nicotine dependence. Participants with higher particle counts more often showed stronger nicotine dependence and lower motivation to quit smoking. These results suggest that circulating Nile Red-positive microparticle counts may differ according to the type of nicotine product used and selected behavioral characteristics. However, the subgroup findings should be interpreted with caution due to the exploratory design and limited statistical power.